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Abstract
The synthesis, spectroscopic characterization and in vitro antitumour activity of two triorganotin
compounds, triphenyltin ortho-aminophenylthiolate (1) and triphenyltin 2-pyridylthiolate,
compound (2) are reported. The structure of 1 is confirmed by X-ray diffraction, with the tin atom in
a distorted tetrahedral geometry because of monodentate coordination, as a thiolate (Sn-,S
2.431(2) A), of the ortho-aminophenylthiolate ligand. The in vitro antitumour activities of 1 and 2,
against a number of cell lines, are comparable to those exhibited by methotrexate and doxorubicin,
and higher than those of carboplatin and cisplatin.
Introduction
Diorganotin bis(2-pyridylthiolates) [1] exhibit an in vitro antitumour activity against MCF-7, a
mammary tumour, and WiDr, a colon carcinoma (ID5o: 300 500 and 900 1300, respectively)
comparable to that of cisplatin (850 and 624).
Because triphenyltin compounds are usually more active than di-n-butyltin derivatives [2], the most
active of the diorganotin compounds, we synthesized triphenyltin ortho-aminophenyl- and 2-
pyridyl-thiolates and screened their the antitumour properties in vitro.
Results and Discussion
Syntheses
Triphenyltin o-aminophenylthiolate, compound 1, and triphenyltin 2-pyridylthiolate, compound 2,
1 NH 2
SnPh3
/
s
were synthesized by the condensation of triphenyltin hydroxide with respectively ortho-
aminothiophenol and 2-pyridylthiol.
X-ray structure of compound 1
Single crystals suitable for X-ray structure determination were obtained for compound 1, but a full
analysis for compound 2 was not obtained (see Experimental). The molecular structure of 1,
shown in Fig. 1, with the main interatomic parameters listed in the caption, is in agreement with a
previous report [3]. The Sn atom exists in a distorted tetrahedral geometry defined by the three
phenyl substituents and the S atom derived from a monodentate ortho-aminophenylthiolate ligand;
Sn-S 2.431(2) . No evidence was found for a significant interaction between the Sn and N(1)
atoms and this accounts for the relatively narrow range of angles about the Sn atom. The amino
group forms two weak interactions with thoe S(1) atom, namely an intramolecular S(1)...H(lb)
interaction of 2.58 .. (S(1)...N(1) is 3.o018(4) A) as well as an interrnolecular S(1)...H(la)’ interaction
of 2.84 (S(1)...N(1)’ is 3.736(4) A., symmetry operation: x, 0.5-y, -0.5+z). It is of interest to
-’nmpare this structure with that of the dimethylated analogue [Ph3Sn(SC6H4NMe2)] [4] for whichVol. 3, No. 2, 1996 Triphenyltin Ortho-Aminophenyl- and 2-Pyridyl-Thiolates
Sn-S(1) is 2.429(1) ,&, and S(1)-C(2)is 1.774(5) ,&, (cf. 1.776(4) ,& in the present study). In the latter
structure there is a close intramolecular Sn...N contact of 2.893(3) A which is responsible for the
opening of a S(1)-Sn-C angle to 121.7(1).
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Figure 1 Molecular structure and crystallographic numbering scheme for triphenyltin ortho-
aminophenylthiolate, 1. Selected interatomic parameters: Sn-S(1) 2.431 (2), Sn-C(11) 2.133(4), Sn-
C(21) 2.126(4), Sn-C(31) 2.134(3), S(1)-C(2) 1.776(4), N(1)-C(2) 1.343(6) A; S(1)-Sn-C(ll) 104.9(1),
S(1)-Sn-C(21) 106.3(1), S(1)-Sn-C(31) 109.2(1), C(11)-Sn-C(21) 115.6(1), C(11)-Sn-C(31) 109.7(1),
C(21)-Sn-C(31) 110.7(1), Sn-S(1)-C(1)97.3(1).
Clearly, the orientation of the amino group away from the Sn atom in 1 occurs to facilitate the forma-
tion .of hydrogen bonding contacts, a situation that can not occur for the dimethylated analogueA full
structure determination could not be achieved for2 because of crystal disorder. The analysis con-
firmed nevertheless the generation of the desired compound and showed that the triorganotin center
is coordinated by the S atom, leading to a distorted tetrahedral geometry; a weak intramolecular
interaction with the pyridine-N atom is evident.
Spectroscopic characterization ofcompounds I and2
13 119 119 The compounds were characterized bylH, C, Sn NMR and Sn MSssbauer spectroscopy (see
13 Experimental Section). 13C assignments were achieved from the comparison of C{ H} standard and
DEPT spectra as well as from aromatic chemical shift increment calculations [6].
The 1j(C-1191117Sn) coupling constants (596/570 Hz) and the 119Sn chemical shift (-116.3 ppm) of
compound 2 suggest a tetrahedral monomeric structure, in agreement with previous NMR data [8].
For compound 1, somewhat lower 1J(13C-119/llFSn) coupling constants (558/533 Hz) are observed,
but a quite different 119Sn chemical shift (-68.0 ppm).These NMR data confirm the data from the solid
state that the intramolecular N-->Sn interaction is stronger in the 2-pyridylthiolate) than in the ortho-
aminophenylthiolate. (1). Thus in solution likewise both the low frequency shift of the 119Sn chemical
13 119/1 shift and the higher J( C- 17Sn) coupling are indicative of a stronger distortion of the tetrahedral
geometry towards five-coordination as a consequence of the weak N->Sn interaction. In contrast, the
MSssbauer data, especially the very close QS values, do not discriminate between slight but signifi-
cant differences in coordination spheres revealed by the NMR and X-ray data.
Antitumour activities of compounds 1 and 2
The in vitro antitumour activities of compounds 1 and 2 were determined against a panel of six human
tumour cell lines, MCF-7 and EVSA-T, two breast cancers, WiDr, a colon cancer, IGROV, an ovarian
cancer, M19 MEL, a melanoma, andA498, a renal cancer; the results are shown inTable 1.
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Table 1 In vitro antitumour activities (ng/mL) of compounds 1 and 2, together with those of some
reference compounds used clinically, against MCF-7 and EVSA-T, two breast cancers, WiDr, a colon
cancer, IGROV, an ovarian cancer, M19 MEL, a melanoma, and A498, a renal cancer.
Compounds MCF-7 EVSA-T WiDr IGROV M19 MEL A498
1 <3 6 24 30 30 36
2 6 8 18 38 30 35
Carboplatin 10500 4500 3500 2400 5500 18000
Cisplatin 1400 920 1550 230 780 1200
5-Fluorouracil 350 720 440 850 310 340
Methotrexate 5 26 7 20 8 1 6
Doxorubicin 25 3 8 150 21 55
The in vitro results show that the two compounds are as active or more active than methotrexate,
and doxorubicin, and significantly more active than carboplatin, cisplatin and even 5-fluorouracil
against all cell lines.
Experimental
Syntheses
Compounds 1 and 2 were prepared by adding 5 mmole of triphenyltin hydroxide to a solution of 5
mmole of respectively ortho-aminothiophenol or 2-thiopyridine in 150 cm3 toluene and 50 cm3
ethanol. After refluxing for 6 h, distilling off the ternary azeotrope water/toluene/ethanol witll a
Dean-Stark funnel and half of the remaining solvent, the resulting mixture was cooled down to room
temperature, filtered and evaporated under vacuum. The residue was recrystallized from
chloroform/n-hexane.
Characterization
MEssbauer data: QS: quadrupole splitting; IS: isomer shift; r’l and F2: line widths, all in mm/s.
NMR data" all spectra were acquired from CDCl3 solutions and referenced to the residual ClHCI3
resonance at 7.24 ppm for the 1H spectrum, to the central 13CDCl3 resonance at 77.0 ppm for the
13C spectrum and to (119Sn) 37.290665 for the 119Sn spectra [5].
Abbreviations for coupling patterns: dd doublet of doublets; ddd doublet of doublets of
doublets; m complex pattern; b broad; coupling constants are given in Hz in parentheses for
nj(H-H) for H spectra. Other coupling constants are indicated explicitly. Calculated chemical
shifts, using incremental rules [6], are given in parentheses.
Compound 1: m.p.: 78-79C; yield: 83 %; MSssbauer data: QS: 1.63; IS: 1.34; ]-’1: 0.85; ]-’2: 0.78;
1H NMR data: 7.51 7.47, m: H(o); 7.40-7.29: H(m) + H(p); 7.19, dd (8, 1): H-3; 6.88, ddd (8, 8, 1):
H-5; 6.48, dd (8, 1): H-6; 6.40, ddd (8, 8, 1): H-4; 4.08, b: NH2;130 NMR data: C-2:115.0 (117.5); C-
1: 148.6 (147.6); C-6:114.6 (116.3); C-5:127.9 (126.3); C-4:118.3 (119.8); C-3:136.7 (130.5);
19/117 13 2 C(i): 137.9 [1j(1 Sn- C) 558/533]; C(o): 136.6 J(19/117Sn-13C) 43]; C(m)" 128.7
119 [3J(19/lFSn-3C) 57]; C(p): 129.7; Sn NMR data:-68.0.
Compound 2: m.p.: 98-100C; yield: 86 %; MSssbauer data: QS: 1.62; IS: 1.26; ]-’1: 0.78; F2: 1.09;
1H NMR data: 7.96, ddd (5, 1, 1): H-6; 7.77 7.63, m: H(o); 7.37 7.27:H-3 + H-4 + H(m) + H(p);
6.76, ddd (7, 5, 2): H-5; 13C NMR data: C-2:160.7 (151..8); C-3:123.6 (124.9); C-4:136.8 (136.5);
119/117 13 C-5:1.18.9 (121.0); C-6:147.9 (150.0); C(i): 141.1 J( Sn- C) 596/570]; C(o): 136.8
2 119/117 13 3 119/117 13 119 J( Sn- C) 44]; C(m): 128.7 J( Sn- C) 60]; C(p): 129.3; Sn NMR data: -116.3.
Instruments
All NMR spectra were recorded on a Bruker AC250 instrument, using a QNP probe tuned at
250.13, 62.93 and 93.28 MHz for 1H, 13C and 119Sn nuclei, respectively.
MEssbauer spectra were obtained as described previously [8].
The in vitro antitumour screenings were performed as described earlier [9].
Crystallography
1: Intensity data for a colorless crystal (0.13 x 40 x 0.40 mm) of 1 were measured at room
temperature on a Rigaku AFC6R diffractometer fitted with MoKo radiation, X 0.71073 ,&,
employing the e):2e scan technique. A total of 4267 data (emax 25.0) were recorded and of
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these 3994 were unique of which 2945 absorption corrected [10] data satisfied the > 3.0s(/)
criterion and were used in the subsequent analysis.
Crystal data for 1: C2H21NSSn, M 474.2, monoclinic, space group P21/c, a 13.11(1), b
19.04(1), c= 9.071(8) A, I] 106.87(7), V= 2166(6) ,,3, Z= 4, DO 1.454 g cm-3, F(000) 952,
12.83 cm-, transmission factors 0.867 to 1.073.
The structure was solved by direct methods [11] and refined by a full-matrix least squares
procedure based on F [12]. Non-H atoms were refined with anisotropic thermal parameters and H
atoms were included in the model at their calculated positions (N-H 0.95 ./x. and C-H 0.97 .&,). At
convergence R 0.027 and Rw 0.030 (sigma weights); the maximum peak in the final difference
map was 0.28e-3. The molecular structure is represented in Fig. (drawn with ORTEP [13] at 35%
probability ellipsoids). Supplementary material (fractional atomic coordinates, thermal parameters, all
interatomic parameters and structure factor tables) are available on request from ERTT.
2: A total of five data sets for different samples of 2 were collected at both room temperature and at
-70C, however, only unsatisfactory analyses were obtained. Whereas the gross structural were
determined (R ca 12%), reliable geometric parameters were not; see text. Crystal data: monoclinic,
space group Cc, a 17.179(5), b 15.256(1), c= 8.142(5) ,/k, [ 109.55(2), V= 2010(1) ,/,3, Z’- 4.
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